Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab
NCT07337395
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Roma, Italy
View Trial DetailsNCT Number: NCT07033559
The goal of this observational study is to learn if computer analysis of voice recordings can detect a type of exhaustion called "central fatigue" in adults with generalised myasthenia gravis.
The main questions it aims to answer are:
1. Can advanced voice analysis accurately tell when participants are experiencing deep exhaustion based on how they speak? 2. How easy and acceptable is voice-based fatigue monitoring for people with myasthenia gravis?
Participants will:
1. Record themselves reading short passages and answering questions out loud twice daily (morning and evening), twice a week, for 4 weeks. 2. Answer brief questionnaires about their energy levels, mood, and myasthenia gravis symptoms during each session. 3. Use their own devices (computer, tablet, or smartphone) to complete all study activities online from home.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
This study addresses a significant gap in understanding and measuring central fatigue in generalised myasthenia gravis (gMG), a debilitating symptom that differs from the characteristic muscle weakness fluctuations of the condition. Central fatigue encompasses mental and physical exhaustion originating in the central nervous system and remains poorly characterised with limited validated assessment tools.
Study Rationale and Innovation:
Recent developments in artificial intelligence and digital biomarkers have demonstrated potential for detecting fatigue-related changes in voice characteristics. This approach offers advantages over traditional assessment methods by providing objective, standardised measurements that can be collected remotely with minimal participant burden. Voice-based biomarkers may capture subtle physiological changes associated with central fatigue that are not readily apparent through conventional questionnaire-based assessments.
Study Design and Methodology:
This single-cohort observational study employs an intensive longitudinal monitoring design to capture the dynamic nature of fatigue fluctuations characteristic of gMG. The twice-daily assessment schedule (morning and evening sessions two days a week) over four weeks is designed to account for diurnal variation in fatigue symptoms commonly reported by MG patients.
Each assessment session lasts approximately 10-15 minutes and includes standardised voice recording tasks alongside validated fatigue questionnaires. Voice recording activities consist of structured reading tasks and answering questions out loud, designed to elicit natural speech patterns while maintaining consistency across sessions and participants.
Technical Approach:
Voice data will be analysed using machine learning algorithms to identify acoustic features potentially associated with central fatigue states. [Note: Specific algorithmic approaches and feature extraction methods are proprietary and not detailed here]. The study uses triangulated participant self-reported fatigue assessments as ground truth labels for model training and validation.
Data Collection and Management:
All data collection occurs remotely through a secure web-based platform accessible via standard internet browsers. Participants use their personal devices (computers, tablets, or smartphones) equipped with microphone capabilities. The platform captures voice recordings, questionnaire responses, and relevant metadata including device specifications and environmental conditions that may affect recording quality.
Sample Size Considerations:
The target enrolment of 240 participants is designed to generate sufficient data points for robust machine learning model development while accounting for expected attrition and technical issues.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Across 16 assessment sessions over 4 weeks from enrolment
Binary classification performance (presence vs. absence of central fatigue) of the artificial intelligence-based system using voice biomarker analysis, with the subjective fatigue scale serving as ground truth. Performance will be measured using sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) metrics through cross-validation methods.
Time frame: From enrolment through completion of final assessment session at 4 weeks
Percentage of enrolled participants who complete all 16 required assessment sessions out of the total number of participants who begin the study
Time frame: From enrolment through completion of final assessment session at 4 weeks
Percentage of individual assessment sessions completed across all enrolled participants out of the total possible sessions
Time frame: From enrolment through completion of final assessment session at 4 weeks
Percentage of completed sessions that occur within the designated time windows out of all completed sessions
Time frame: At completion of final assessment session at 4 weeks
Self-reported acceptability scores including ease of use, satisfaction, and willingness for future use of the voice-based fatigue monitoring approach, assessed through three researcher developed 7-point Likert scales (1=lowest, 7=highest)
Time frame: From enrolment through 4 weeks or until participant withdrawal
Number and percentage of participants who withdraw from the study, categorised by stated reasons for withdrawal (technical difficulties, time burden, health reasons, other)
Time frame: 4 weeks
Correlation between AI-detected central fatigue severity scores (0 = low to 1 = high) and self-reported peripheral fatigue symptoms measured by subscales of the MG-Symptoms PRO, namely "physical fatigue" and "muscle weakness fatigability" (Regnault et al., 2024). The score for each scale ranges from 0 to 100, with higher values indicating more severe symptoms. Analyses will employ Spearman's rank correlation to account for potential non-linear relationships.
Time frame: 4 weeks
Correlation between central fatigue measures (both self-reported using the Modified Fatigue Impact Scale (MFIS) and AI-detected probability scores between 0 = low and 1 = high) and depression (PHQ-8) and anxiety (GAD-7) scores. The MFIS uses a 5-point scale from 0 = never to 4 = almost always with a total score range of 0-84. The PHQ-8 and GAD-7 use 4-point scales from 0 = not at all to 3 = nearly every day, with total score ranges of 0-24 for PHQ-8 and 0-21 for GAD-7.
Contact information is provided by the study sponsor or research team.
Alexandra L Georgescu, PhD
CONTACT
Emilia Molimpakis, PhD
CONTACT
Thymia Limited
Industry
Remote Digital Voice Biomarkers for Central Fatigue Detection in Generalised Myasthenia Gravis: An Online Single-Cohort Observational Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07337395
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Roma, Italy
View Trial DetailsNCT06617741
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Westborough, Massachusetts, United States
View Trial DetailsNCT06906692
Complement System, Myasthenia Gravis Generalised
Rome, RM, Italy
View Trial DetailsNCT00408213
Myasthenia Gravis Generalised
Sun City, Arizona, United States
View Trial Details